Aurique Limited boards meet on Aug 6 to consider fund raising options
Aurique Limited's Board of Directors will meet on August 06, 2026, to consider raising funds through equity shares, warrants, or convertible securities via rights issues or private placements. The proposal requires shareholder approval at an Extra-Ordinary General Meeting and relevant regulatory clearances as per SEBI LODR Regulations.

*this image is generated using AI for illustrative purposes only.
Aurique Limited (formerly known as PAE Limited) has intimated that its Board of Directors will convene on August 06, 2026, to evaluate strategic options for raising capital. The primary objective of the meeting is to deliberate on a proposal for fund raising by the company, potentially involving the issue of securities including equity shares or other equity-linked instruments. This move signals the company’s intent to strengthen its financial position or fund expansion plans, subject to the terms and conditions deemed appropriate by the board.
The proposal encompasses a range of permissible modes for raising funds under the Companies Act, 2013, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. Specifically, the board may consider issuing warrants, convertible securities other than warrants, or any other eligible securities. These instruments could be issued through a rights issue, preferential allotment, or a private placement. The decision on the specific mode and terms rests with the Board of Directors, including its committees, acting in their absolute discretion.
Regulatory and Shareholder Approvals
Any resolution passed by the board regarding the fund raising exercise is contingent upon further approvals. The company intends to convene an Extra-Ordinary General Meeting (EGM) to seek approval from its shareholders for the proposed fund raising activities. Additionally, the transaction will require receipt of other necessary regulatory and statutory approvals before implementation. The filing was made pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
| Agenda Item | Details |
|---|---|
| Meeting Date | August 06, 2026 |
| Primary Purpose | Proposal for fund raising via equity-linked instruments |
| Potential Instruments | Equity shares, warrants, convertible securities |
| Issuance Modes | Rights issue, preferential allotment, private placement |
| Required Approvals | Shareholder approval (via EGM), regulatory/statutory approvals |
Company Profile and Contact Information
Aurique Limited is listed on the Bombay Stock Exchange (BSE) under the symbol AURIQUE with Scrip Code 517230 and ISIN INE766A01026. The company’s registered office is located at Level 1, Block A, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai-400018, Maharashtra, India. Its corporate office is situated at A-1115 Titanium Business Park, Nr Makarba Railway Crossing, Jivraj Park, Ahmedabad-380051, Gujarat, India.
The intimation was signed by Sarah Kantharia, the Company Secretary and Compliance Officer of Aurique Limited. For further inquiries, stakeholders may contact the company via email at compliance.pae@gmail.com or visit www.paeltd.com .
What specific expansion projects or debt restructuring initiatives is Aurique Limited likely targeting with this capital raise?
How might the potential dilution from issuing equity-linked instruments impact existing shareholder value and voting power?
Will the company prioritize a rights issue to treat all shareholders equally, or will it opt for a preferential allotment to bring in strategic investors?





























